CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)	Preferred Stock Series A	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2013		$ 5	$ 13,131,233	$ (1,379,654)	$ 11,751,584
Balance, (in shares) at Dec. 31, 2013		46,327
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Offering costs incurred in 2014 pertaining to December 2013 offering			(109,104)		(109,104)
Issuance of common stock for services			1,602,933		1,602,933
Issuance of common stock for services (in shares)		1,143
Issuance of common stock in connection with exercise of stock options			5,000		5,000
Issuance of common stock in connection with exercise of stock options (in shares)		14
Issuance of common stock in connection with cashless exercise of warrants (in shares)		407
Discount on senior convertible notes			1,250,000		1,250,000
Stock-based compensation expense			163,646		163,646
Net income (loss)				(13,852,249)	(13,852,249)
Balance at Dec. 31, 2014		$ 5	16,043,708	(15,231,903)	811,810
Balance, (in shares) at Dec. 31, 2014		47,891
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with the Merger (See Note 3)		$ 4	17,028,395		17,028,399
Issuance of common stock in connection with the Merger (See Note 3) (in shares)		38,833
Issuance of common stock and warrants in connection with private placement, net of offering costs		$ 1	447,320		447,321
Issuance of common stock and warrants in connection with private placement, net of offering costs (in shares)		9,807
Reclassification of conversion option from liability to equity			13,300		13,300
Contribution of note and interest payable to Vaporin to capital in connection with the Merger			354,029		354,029
Cancellation of common stock as a result of early termination of consulting agreement (in shares)		(429)
Issuance of common stock in connection with consulting services			143,000		143,000
Issuance of common stock in connection with consulting services (in shares)		393
Issuance of common stock in connection with delivery of restricted stock units		$ 1	(1)
Issuance of common stock in connection with delivery of restricted stock units (in shares)		5,094
Issuance of common stock in connection with waiver deferral agreements			1,328,196		1,328,196
Issuance of common stock in connection with waiver deferral agreements (in shares)		9,256
Warrants issued or modified in connection with convertible note payable			124,211		124,211
Issuance of common stock in connection with waiver agreement		$ 4	1,297,077		1,297,081
Issuance of common stock in connection with waiver agreement (in shares)		37,098
Issuance of Series A Units, Series A preferred stock and warrants in connection with underwritten offering	$ 13		927		940
Issuance of Series A Units, Series A preferred stock and warrants in connection with underwritten offering (in shares)	13,434
Issuance of unit purchase option to underwriter in connection with Series A Units, Series A preferred stock and warrants			1,552,418		1,552,418
Stock-based compensation expense			582,356		582,356
Deemed dividend on issuance of Series A Units, Series A preferred stock and warrants			(38,068,021)		(38,068,021)
Net income (loss)				1,800,753	1,800,753
Balance at Dec. 31, 2015	$ 13	$ 15	$ 846,915	$ (13,431,150)	$ (12,584,207)
Balance, (in shares) at Dec. 31, 2015	13,434	147,943